IRIS-PREMIER REGISTRY
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 2000
Inclusion Criteria
- Age 20 and more
- Intervention with Promus PREMIER everolimus eluting coronary stent
- Agreed with written informed consent form
- Age 20 and more
- Intervention with Promus PREMIER everolimus eluting coronary stent
- Agreed with written informed consent form
Exclusion Criteria
- Life expectancy of 1year and under
- Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
- Cardiac shock
- Life expectancy of 1year and under
- Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
- Cardiac shock
Summary
- Conditions
- Coronary (Artery) Disease
- Coronary Disease
- Heart Diseases
- Myocardial Ischemia
- Coronary Artery Disease
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 20 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Age 20 and more
- Intervention with Promus PREMIER everolimus eluting coronary stent
- Agreed with written informed consent form
- Age 20 and more
- Intervention with Promus PREMIER everolimus eluting coronary stent
- Agreed with written informed consent form
Exclusion Criteria
- Life expectancy of 1year and under
- Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
- Cardiac shock
- Life expectancy of 1year and under
- Intervention with Promus PREMIER everolimus eluting coronary stent and other drug eluting stent at the same time
- Cardiac shock
Tracking Information
- NCT #
- NCT02060968
- Collaborators
- CardioVascular Research Foundation, Korea
- Boston Scientific Korea Co. Ltd
- Investigators
- Not Provided
Get Well Soon